US Stock Market Move | Treatment of genetic bone diseases in the research drug clinical trial failed, Ultragenyx Pharmaceutical (RARE.US) plunges over 42% in pre-market trading.
As of the filing, the stock is down over 42%, trading at $19.69.
Before Monday's US stock market opening, Ultragenyx Pharmaceutical (RARE.US) stock price plummeted. As of press time, the stock has fallen more than 42% to $19.69. On the news front, the company announced that its investigational drug for treating a specific genetic bone disease did not meet the primary efficacy endpoint in late-stage clinical trials.
Related Articles
Jin Xun Resources (03636) held its IPO from December 31st to January 6th and received approximately 60.26 million US dollars in cornerstone investments.
GigaDevice Semiconductor Inc. (03986) conducted its IPO from December 31st to January 8th, raising approximately $2.997 billion in cornerstone investment subscriptions.
China Securities Co., Ltd.: From over-the-counter trading and local direct procurement to tri-city cellaring, in-depth analysis of central bank gold purchases.
Jin Xun Resources (03636) held its IPO from December 31st to January 6th and received approximately 60.26 million US dollars in cornerstone investments.
GigaDevice Semiconductor Inc. (03986) conducted its IPO from December 31st to January 8th, raising approximately $2.997 billion in cornerstone investment subscriptions.
China Securities Co., Ltd.: From over-the-counter trading and local direct procurement to tri-city cellaring, in-depth analysis of central bank gold purchases.
